roidism, which must have contributed to the pathogenesis of hypocalcaemia. The hyposecretion of iPTH in these patients is probably secondary to several factors including hypomagnesaemia, which inhibits the secretion of iPTH both in vivo and in vitro.29 Antimicrobial and cytotoxic drugs may also have an inhibitory effect on iPTH secretion. Vinblastine, for instance, disrupts the morphology of the parathyroid gland.10 Aminoglycosides have been incriminated in the pathogenesis of hypoparathyroidism,3 but in our series two patients developed the syndrome in the absence of aminoglycoside treatment. All nine patients, however, had been taking doxorubicin (or daunorubicin) and cytarabine; these drugs may have contributed to the suppression of parathyroid secretion.
roidism, which must have contributed to the pathogenesis of hypocalcaemia. The hyposecretion of iPTH in these patients is probably secondary to several factors including hypomagnesaemia, which inhibits the secretion of iPTH both in vivo and in vitro.29 Antimicrobial and cytotoxic drugs may also have an inhibitory effect on iPTH secretion. Vinblastine, for instance, disrupts the morphology of the parathyroid gland.10 Aminoglycosides have been incriminated in the pathogenesis of hypoparathyroidism,3 but in our series two patients developed the syndrome in the absence of aminoglycoside treatment. All nine patients, however, had been taking doxorubicin (or daunorubicin) and cytarabine; these drugs may have contributed to the suppression of parathyroid secretion.
In conclusion, we have described a syndrome that consists of a combination of hypocalcaemia, hypomagnesaemia, and a state of absolute or relative hypoparathyroidism in patients receiving treatment for acute leukaemia. In our series the syndrome was common and led to profound clinical problems, including tetany. The condition appears to be multifactorial and requires further investigation. Awareness of this metabolic problem allowed us to intervene therapeutically and to reduce morbidity. We subsequently prevented any appreciable decrease in plasma calcium and magnesium concentrations by giving appropriate supplements and lcx-hydroxycholecalciferol. Despite this concentrations of parathyroid hormone remained low (unpublished data). Control of anticoagulant treatment was studied in 250 patients. One hundred and fifty patients receiving longterm anticoagulant treatment (group 1) were studied for 52 weeks and the remaining 100 (group 2) for 12 weeks after discharge from hospital. The desired British corrected ratio range was 2 5-3-3, and a range of 2-3-3-5 was classified as satisfactory. In group 1 a satisfactory ratio was obtained for 70% of the study period and 120 of the 150 patients were maintained within this range for over 60% of the time. In group 2 only half of the patients were maintained within the satisfactory range and for 50% of the study period or less. The time and effort expended in therapeutic control were more than most clinics could afford, and the results for group 2 were disappointing.
Introduction
In the early days of anticoagulant treatment haemorrhage was a real danger owing to the variable sensitivities of thromboplastins, and as a result most patients received insufficient treatment. In his historical review of anticoagulant treatment Loeligerl stated that a ratio range of 2-0-2-5 was recommended by the American Heart Association based on the earlier work of Allen et a 12 3and Wright et al,4 who had suggested ranges of 1-5-3-0 and 2-0-3-0 respectively. At the time this was considered to be adequate and safe. With the standardisation of thromboplastins by the introduction of British comparative thromboplastin by Poller5 6 and the "external quality assessment scheme"7 that followed, anticoagulant treatment was placed on a safer foundation. Higher ratio ranges are now recommended, especially for patients who have had open-heart surgery. Blackburn8 recommended a British corrected ratio (BCR) of 2-0-4-0 based on clinical experience, but Poller9 found that haemorrhage was rare in hospitals using British comparative thromboplastin as a reagent and suggested that a BCR of 5 0 was a safe upper limit for hospital patients with active thrombosis. Loeligerl proposed that the optimum therapeutic range should be 3 0-5 0 for inpatients and 2-5-4-5 for outpatients. For patients with artificial heart valves Boekhout-Mussert et al'0 advised a higher range, equivalent to a BCR of 3 0-5 0.1 The range adopted for the "Dutch trial"" in elderly patients after myocardial infarction was 2-7-4-5.
The effectiveness of attempting to achieve higher ratio ranges therefore requires confirmation.
Patients and methods I reviewed anticoagulant ratios in 250 patients. A third of the patients had received heart-valve replacements or coronary artery grafts. The others suffered from multiple myocardial infarctions, recurrent pulmonary embolism, heart-valve disease, atrial fibrillation, recurrent deep-vein thrombosis, and arterial vascular disease, and so were an average selection of patients attending anticoagulant clinics. For this investigation all were anticoagulated to the same degree to see how the ratio range could be maintained.
The patients were divided into two groups: group 1 consisted of 150 long-term patients, who were reviewed for 52 weeks (1980), and group 2 consisted of 100 patients treated for three months after discharge from hospital.
As British comparative thromboplastin consistently gave a control time of 12 + 0 5 s when Quick's test was performed with a prothrombintime meter (Clotek; Hyland) the defined ranges were based on prothrombin times in seconds as in table I. Though overanticoagulation is not advisable for the safety of patients, it is nevertheless satisfactory for inhibition of thrombosis, and so there was some bias in group 2 and a BCR range of 2-3-4-2 was considered to be satisfactory (ranges A+B).
Results
Group 1- Table II shows the average percentage of time for which the defined ratio ranges were recorded in the 150 patients over 52 weeks. The satisfactory range (BCR 2-3-3-5) was attained for nearly 700o of the time; the range indicated insufficient or inadequate anticoagulation for 25% of the time. Sixty-three patients (42%) were maintained within the satisfactory range for 60-70% of the time and 57 (38%) for over 75% of the time, so that 120 patients (80%) were maintained in the satisfactory range for more than 60% of the time. Thirty (20%) patients were maintained in the satisfactory range for only 50% or less of the time.
Group 2-Just over half (51) of the 100 patients given anticoagulant treatment for three months after discharge from hospital were maintained in the satisfactory range for only 50% or less of the time; 34 were maintained in this range for 60-75% of the time and 15 for over 75% of the time. Table III shows the number of patients whose ratio was maintained in the satisfactory range during each week of the three months: more patients were adequately controlled during the first week of each month, after which dose requirements altered and it took the remainder of the month to bring the patients back in control. Even in the good week of the month, however, only 40 of the patients were under adequate control. Some patients were brought under control only during the last month, just before treatment was due to be stopped. Another difficulty is that the response to anticoagulants is affected by so many factors (for example, patient non-compliance, individual resistance or sensitivity,13 dietary change,'4 and drug interactionsl5 -17), which thwart the maintenance of good 
(1) therapeutic control. Because of these difficulties patients must be seen more often to maintain good therapeutic control: this is expensive in manpower and time and more than most hospitals can afford. Harries et all8 and McInnes"9 confirmed that junior staff always play for safety when prolonged intervals are in use, and as a result underanticoagulation is the most common defect of control. Mitchell20 pointed out that so many statistical errors were made in the early trials of anticoagulant treatment, and the quality of thromboplastins was so poor and variable then, that the findings of most of these trials must be considered to be invalid.
The findings of the early Medical Research Council trials of anticoagulant treatment after myocardial infarction21 -23 were equivocal except for a reduction of the secondary effects of intramural thrombi. The value of anticoagulant treatment in this condition has therefore fallen into disrepute recently, and few now continue anticoagulant treatment for long after patients are discharged from hospital. The recent "Dutch trial,"1 avoiding the errors of early trials and maintaining the therapeutic ratio range within close limits, showed that intensive and stable anticoagulant treatment substantially reduced the risk of recurrent myocardial infarction. This suggests that early trials failed due to inadequate control of treatment.
Over the next few years the number of patients receiving long-term anticoagulant treatment will increase owing to the reassessment of these new trials and the increased number of patients undergoing cardiac surgery.
Recommendation-Anticoagulant treatment is expensive and is not cost effective. It is invariably delegated to rotating junior staff, who may not have had previous experience, and so there is no consistent control. Medical assessment of anticoagulant treatment should be started. The method described here is simple and may be recorded in the patients' record cards after each visit. The "score" may then be evaluated annually. British comparative thromboplastin and the associated quality assessment scheme has given anticoagulant treatment a safe foundation. With the higher therapeutic BCR ranges now being advocated therapeutic quality control is required so that this expensive and potentially dangerous treatment may be used to the greatest effect. Lhermitte's sign consists of a sudden tingling or sensation of electric shock in the limbs on flexion of the neck and was originally thought to be pathognomonic of multiple sclerosis.2 It is now recognised as occurring in various conditions affecting the cervical cord and cervicomedullary junction.3 We observed this sign to be a prominent feature in two patients with Behqet's disease.
SHORT REPORTS
Case reports CASE 
1
An 18-year-old Cypriot developed shock-like sensations "like a flash of blood or electricity" in his legs and arms on flexion of the neck. This persisted and was followed by left-sided hypoesthesia, leg weakness, and incoordination. He had suffered arthritis of the hands at the age of 15 A 45-year-old woman developed neurological disease. Behcet's disease had been diagnosed nine years earlier on the basis of longstanding painful mouth and genital ulcers, polyarthralgia, and uveitis. She had been treated intermittently with steroids and immunosuppressives. She later complained of right-sided weakness and "brisk electric shocks" down her right side on flexion of the neck. These were momentary, shooting from the neck to the fingers and toes.
She was mildly cushingoid with active arthritis, orogenital ulceration, and anterior and posterior uveitis. Neurological examination showed reduced sensation on the right, including joint position and vibration sense. There was mild pyramidal weakness on the right but no evidence of incoordination or nystagmus. Lhermitte's sign remained present. Investigations showed an
